Freedom Biosciences is a Yale spin-out and clinical-stage biotech platform developing next gen neuropsych combo drugs. The company's lead program for Treatment Resistant Depression is ~18 months from a major inflection point - the readout of Phase 2a (n=120). The company is co-founded by the Chair of Psychiatry at Yale and run by the top biotech execs from Johnson & Johnson and Biohaven (acquired $11.6b by Pfizer). The lead program (Free001 “extended efficacy” ketamine) showed 3x longer duration of antidepressant effect than ketamine & esketamine: 14-21 days in antidepressant effects vs. 2-7 days for ketamine and esketamine SPRAVATO. Free001 is positioned to build upon the success of Jannsen’s Esketamine SPRAVATO, which is $1B+ ARR drug and the fastest growing program in Jannsen’s portfolio, which is now approved 80+ markets, including China.